Compare XTNT & CING Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | XTNT | CING |
|---|---|---|
| Founded | N/A | 2012 |
| Country | United States | United States |
| Employees | N/A | 13 |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 88.7M | 93.1M |
| IPO Year | 2009 | N/A |
| Metric | XTNT | CING |
|---|---|---|
| Price | $0.58 | $7.17 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 2 |
| Target Price | $1.50 | ★ $37.00 |
| AVG Volume (30 Days) | 99.1K | ★ 563.8K |
| Earning Date | 03-06-2026 | 03-18-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.03 | N/A |
| Revenue | ★ $53,337,000.00 | N/A |
| Revenue This Year | $15.08 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $19.34 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.34 | $3.20 |
| 52 Week High | $0.95 | $11.89 |
| Indicator | XTNT | CING |
|---|---|---|
| Relative Strength Index (RSI) | 47.83 | 48.32 |
| Support Level | $0.55 | $3.77 |
| Resistance Level | $0.68 | $7.92 |
| Average True Range (ATR) | 0.05 | 1.06 |
| MACD | -0.00 | -0.04 |
| Stochastic Oscillator | 26.21 | 17.71 |
Xtant Medical Holdings Inc is a medical technology company focused on the design, development, and commercialization of a comprehensive portfolio of orthobiologics and spinal implant systems to facilitate spinal fusion in complex spine, deformity and degenerative procedures. Its products are used by orthopedic spine surgeons and neurosurgeons to treat a variety of spinal disorders in the cervical, thoracolumbar, and interbody spine. The company's biomaterial products include OsteoSponge, OsteoSponge SC, OsteoSelect Plus DBM putty, OsteoWrap, and the line of 3Demin products, as well as other allografts. It generates a majority of its revenue from the U.S.
Cingulate Inc is a clinical-stage biopharmaceutical company utilizing its proprietary precision timed-release drug delivery platform to build and advance a pipeline of next-generation pharmaceutical products designed to improve the lives of patients suffering from frequently diagnosed conditions characterized by burdensome daily dosing regimens and suboptimal treatment outcomes. The company focuses on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD) and anxiety, and identifying and evaluating additional therapeutic area to use PTR technology to develop future product candidates.